Trials / Completed
CompletedNCT02843815
Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced NSCLC.
Detailed description
By enrolling patients with NSCLC adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and nature killer (NK) cells for NSCLC. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Cryosurgery | Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance) |
| BIOLOGICAL | NK Immunotherapy | Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.) |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-07-01
- Completion
- 2019-07-01
- First posted
- 2016-07-26
- Last updated
- 2019-09-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02843815. Inclusion in this directory is not an endorsement.